Cardiology, Gene Editing and Genetics - Clinical Research Informer

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

Cardiology

Gene Editing

Genetics

STAT+: Verve Therapeutics begins human tests of first ‘base editor,’ aiming at heart disease

STAT News

JULY 12, 2022

Somewhere in New Zealand, the first patient ever has been dosed with a kind of gene-editing treatment known as a base editor, a newer way of utilizing CRISPR for gene editing. The company studying the treatment, Verve Therapeutics, announced the news Tuesday.

Gene Editing

Gene Editing Gene Therapy Gene Cardiology

Advancing gene editing with new CRISPR/Cas9 variant

Scienmag

DECEMBER 3, 2020

Using a new variant to repair DNA will improve both safety and effectiveness of the much-touted CRISPR-Cas9 tool in genetic research, Michigan Medicine researchers say. Eugene Chen, M.D., […].

Gene Editing

Gene Editing Gene DNA Genetics

Vutrisiran Reduces Heart Risks for ATTR-CM Patients in Alnylam’s HELIOS-B Trial

XTalks

SEPTEMBER 4, 2024

The data, presented at the European Society of Cardiology Congress 2024, suggest that vutrisiran could significantly reduce the risk of death and heart-related issues, marking a potential treatment breakthrough.

Trials

Trials RNA Protein Gene Editing

STAT+: Verve Therapeutics begins human tests of first ‘base editor,’ aiming at heart disease

Advancing gene editing with new CRISPR/Cas9 variant

Vutrisiran Reduces Heart Risks for ATTR-CM Patients in Alnylam’s HELIOS-B Trial

Stay Connected